Liraglutide vs Survodutide

Liraglutide is a GLP-1 receptor agonist already approved by the FDA to treat type 2 diabetes, obesity, and cardiovascular risk reduction, sold under the brand names Saxenda and Victoza. Survodutide, on the other hand, is a dual-acting drug that targets both GLP-1 and glucagon receptors and is still in development, with no FDA approvals yet. Liraglutide is taken as an injection, while the delivery method for survodutide has not been specified in the provided details.

AI summary of the sources below.